Soluble intercellular adhesion molecule (ICAM)-1 detects invasive fungal infections in patients following liver transplantation
Despite antifungal prophylaxis, liver transplanted patients are endangered by invasive fungal infections (IFI). Routinely used microbiological procedures are hallmarked by significant weaknesses, which may lead to a delay in antifungal treatment. Culture-based fungal findings, routinely used biomark...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 2020
|
| In: |
Biomarkers
Year: 2020, Volume: 25, Issue: 7, Pages: 548-555 |
| ISSN: | 1366-5804 |
| DOI: | 10.1080/1354750X.2020.1810318 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/1354750X.2020.1810318 Verlag, lizenzpflichtig, Volltext: https://www.tandfonline.com/doi/full/10.1080/1354750X.2020.1810318 |
| Author Notes: | Sebastian O. Decker, Anne Incamps, Henryk Wilk, Florian Uhle, Thomas Bruckner, Alexandra Heininger, Stefan Zimmermann, Arianeb Mehrabi, Markus Mieth, Karl Heinz Weiss, Markus A. Weigand and Thorsten Brenner |
| Summary: | Despite antifungal prophylaxis, liver transplanted patients are endangered by invasive fungal infections (IFI). Routinely used microbiological procedures are hallmarked by significant weaknesses, which may lead to a delay in antifungal treatment. Culture-based fungal findings, routinely used biomarkers of infection/inflammation (e.g., procalcitonin or C-reactive protein), as well as corresponding plasma concentrations of soluble Intercellular Adhesion Molecule (ICAM)-1 were analysed in 93 patients during a period of 28 days following liver transplantation (LTX). Plasmatic sICAM-1 was significantly elevated in patients affected by an IFI within the first 28 days in comparison to fungally colonised or unobtrusive LTX patients. sICAM-1 might therefore be helpful for the identification of IFI patients after LTX (e.g., Receiver Operating Characteristic (ROC)-Area Under the Curve (AUC): 0.714 at 14d after LTX). The diagnostic performance of sICAM-1 was further improved by its combined use with different other IFI biomarkers (e.g., midregional proadrenomedullin). The diagnostic deficiencies of routinely used microbiological procedures for IFI detection in patients after LTX may be reduced by plasmatic sICAM-1 measurements. Clinical Trial Notation. German Clinical Trials Register: DRKS00005480 |
|---|---|
| Item Description: | Gesehen am 09.03.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1366-5804 |
| DOI: | 10.1080/1354750X.2020.1810318 |